Cipralex in Treatment of Depressive Symptoms and Chronic Back Pain
WithdrawnPhase 4NCT00227292
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Chronic low back pain (CLBP) is one of the most frequent forms of chronic pain and can result in significant functional impairment. This is often associated with major depression too. Previous research reported significant beneficial effects of antidepressant medication in alleviating depression and pain intensity. The aim of this study is to evaluate the efficacy of Escitalopram, a new kind of Selective Serotonin Reuptake Inhibitor (SSRI) in patients with CLBP in a prospective, randomized and double-blind clinical trial. The main hypothesis is: -in comparison to placebo, subjects with CLBP and Cipralex report a significant reduction in depressive symptoms (\>= 50% of HAMD questionnaire) after 4 weeks of treatment.
Study details
- Official title
- Cipralex in Treatment of Depressive Symptoms and Chronic Back Pain
- Conditions
- Interventions
- Drug: Escitalopram
- Drug: Placebo
- Sponsor
- Martin-Luther-Universität Halle-Wittenberg
- Start date
- 2007-11
- Primary completion
- 2012-11
- Sex
- All
- Age range
- from 18 Years to 65 Years
- Results posted
- No results posted in this snapshot
- Countries
- Germany
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * In- and out-patients at KH Bethanien, Greifswald, presenting with non-specific chronic low back pain lasting longer than 6 months (assessed with VAS and OLBPQ rev.) * Age from 18 to 65 years * Depressive symptoms (HAMD scores \>10) * Significant disability in daily living tasks (Owestry Disability Index \>30%) * Medication with nonsteroidal anti-inflammatory drugs. Exclusion Criteria: * Other significant Axis I disorders, including psychosis, eating disorders, substance use disorders or recent suicidal behavior. * Systemic inflammatory disorder, malignancy, other acute medical or neurological disorders, recent surgery within 12 months. * Medication with opioids, corticosteroids, other psychotropic medication except Temazepam. * History of gastric ulcer, gastritis or gastric bleeding. * Known allergy or intolerance to Citalopram or Cipralex. * Pregnant or lactating women.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00227292